Top 50 Biotechnology Startup Investors in Australia in September 2025
A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotechnology startups based in Australia. We rank investors based on the number of investments they made in Biotechnology companies from Australia. We update this investor list every month.Top 50 Biotechnology Startup Investors in Australia in September 2025
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Diraq — Diraq aims to redefine scalable quantum computing and bring practical commercial applications to the world.
- Celosia Therapeutics — The Celosia Therapeutics approach is the result of advances in gene therapies and a better understanding of the molecular pathways that contribute to neurodegenerative diseases.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Funding Round
- Australia, United States, United Kingdom
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
- AdvanCell — AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing an innovative pipeline of targeted alpha therapies.
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Glyscend Therapeutics — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Seed, Funding Round, Series A
- Australia, United States, United Kingdom
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Lenexa Medical — Lenexa Medical is driving towards better healthcare solutions for patients in hospital and aged-care by preventing pressure injuries and empowering clinicans.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Seed, Series A, Series B
- Australia, United States, Philippines
Portfolio highlights
- Diraq — Diraq aims to redefine scalable quantum computing and bring practical commercial applications to the world.
- Levur — Levur produces oils inspired by nature, without the environmental impact. Our vision is a future where reliance on unsustainable plant and animal oils like Palm Oil is drastically reduced, mitigating environmental impacts. We are collaborating with large consumer goods manufacturers to make this a
- QuintessenceLabs — Quantum cyberattacks can break current encryption in minutes! Get protected with QuintessenceLabs quantum key distribution, generation, and management.
Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.
Show more
Investment focus
- Biotechnology, Information Technology, Manufacturing
- Angel, Seed, Funding Round
- Australia, United States, New Zealand
Portfolio highlights
- Insite AI — The chosen partner by executives in RGM, insights, and I.T. to grow revenue and market share. Learn how CPGs win in pricing, assortment, trade and more.
- Seitec — Seitec is a security company that manufactures seismic security applications and instruments for civilian and military markets.
- Auric Essentials — Auric - The Power of Scent. Revolutionise your well-being with Auric. Discover our state-of-the-art AI-powered AromaSphere diffuser and app, designed to personalise your aromatherapy experience.
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Pre-Seed, Series A
- Australia, United States, Hong Kong
Portfolio highlights
- Voltavate — Voltavate is dedicated to driving innovation in battery technology to support the global transition towards sustainable energy solutions.
- Strong Room AI — Software that enables high-strength care through streamlined workflows, continuous analytics, surfaced insights and safeguarded data.
- SAMA Fertility — SAMA Fertility is a virtual fertility clinic that offers fertility care and treatments, including preservation and evaluation services.
Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.
Show more
Investment focus
- Software, Health Care, SaaS
- Seed, Angel, Series A
- Australia, United States
Portfolio highlights
- Okkular — Okkular is an AI based fashion tech startup.
- Apollo Secure — Cyber for Humans - an automated cybersecurity platform for startups and small businesses to improve security maturity and simplify security compliance.
- Mary Technology — Generate detailed chronologies from documents in minutes with Mary Technology. Achieve 90%+ time reduction and ensure 99%+ accuracy. Try for free.
OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Debt Financing, Funding Round
- Australia, United States, Israel
Portfolio highlights
- Hometime — At Hometime, we provide Airbnb property management solutions for homeowners and rental management business owners that help them scale and earn more.
- StrongDM — Manage access to any server, database, or Kubernetes instance in minutes. Fully auditable, replayable, secure, and drag-and-drop easy.
- Employment Hero — Recruitment, HR, Payroll & Benefits in one place - designed for small & medium businesses to be efficient, compliant & cost-Effective. Book a demo today!
Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.
Show more
Investment focus
- Information Technology, Software, Artificial Intelligence
- Seed, Angel, Funding Round
- Australia, United States, New Zealand
Portfolio highlights
- Tendl — Write tenders faster with Tendl's AI tool. Keep your data private and secure. Easy installation, no sharing. Boost productivity and streamline your contract opportunities.
- Shopfront — Automate multi-channel selling across eBay, Depop, Grailed & Shopify. AI-powered listings, bulk uploads, inventory sync. Join 10,000+ sellers saving 15+ hours weekly.
- Auric Essentials — Auric - The Power of Scent. Revolutionise your well-being with Auric. Discover our state-of-the-art AI-powered AromaSphere diffuser and app, designed to personalise your aromatherapy experience.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
- Biotechnology, Artificial Intelligence, Software
- Series A, Series B, Seed
- United States, United Kingdom, Canada
Portfolio highlights
- Xampla — Xampla's natural plant polymer technology is the innovative technology powering materials to change the world with plastic-free replacements and more.
- Harrison.ai — And a thirst for knowledge meets a passion for a better world.A world where people are cared for by people, medical data analysis is done at scale,
- Owlstone Medical — Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease, and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novelnon-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA Breath Sampler ensures a reliable collection of breath samples. The volatile organic compounds (VOCs) present in the breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by the therapeutic response. The company also Breath Biopsy products and services to academic, clinical, and pharma partners who want to develop breath-based diagnostics for their own applications.
Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.
Show more
Investment focus
- Software, Enterprise Software, Information Technology
- Series A, Series B, Funding Round
- United States, Australia, Philippines
Portfolio highlights
- Aktana — Build stronger relationships with HCPs using Aktana's artificial intelligence (AI) platform for life sciences to optimize omnichannel engagement.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,303,636 freelance designers compete to create amazing designs for your business. Start Today!
- Marani — Marani helps maternity providers quickly identify and manage maternal and fetal risk as well as empowering moms to have healthier pregnancies.
Ip Group Australia build and support outstanding intellectual property-based companies.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Seed, Pre-Seed, Series A
- Australia, New Zealand
Portfolio highlights
- Azaneo — Azaneo develops lightning-fast electric weeding technology. Using only electrons - herbicide free.
- Hysata — Hysata is a developer of hydrogen electrolyzer designed to accelerate the world's shift away from fossil fuels to green hydrogen
- ElectraLith — ElectraLith develops direct lithium extraction and refining technology designed for efficient and sustainable lithium production.
The Clean Energy Finance Corporation invests using a commercial approach to overcome market barriers and mobilize investment in renewable energy, energy efficiency, and low emissions technologies. They seek to catalyze and leverage private sector funding for the commercialization and deployment of clean energy technologies necessary for thetransition to a carbon-constrained economy.
Show more
Investment focus
- Energy, Renewable Energy, Real Estate
- Debt Financing, Funding Round, Series B
- Australia, United States, Spain
Portfolio highlights
- Ampol — Ampol connects our proud history with everything our business is known for today, our trusted high-quality products, our commitment to customer service, local communities and the largest leading transport fuels network in Australia.
- Neoen — Neoen is an independent energy company, develops, finances, builds, and operates power plants based on renewable energies in France, Portugal, Australia, Mexico, Egypt, and El Salvador. It operates solar, wind, and biomass power plants. The company, through its subsidiaries, also specializes in the development of marine renewable energy projects inFrance; supports photovoltaic project developers and investors in the design, construction, operation, and maintenance of solar power plants in France and abroad; and develops solar and wind farms.
- JET Charge — Australia's #1 supplier and installer of EV charging stations for homes and businesses, expert solutions for all EV infrastructure needs.
QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Series A
- Australia
Portfolio highlights
- Verva Pharmaceuticals — Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined productportfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
- Protagonist Therapeutics — Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.
Backing a better tomorrow
Show more
Investment focus
- Renewable Energy, Software, Biotechnology
- Series A, Seed, Series B
- Australia, United States, Singapore
Portfolio highlights
- Gridmo — gridmo accelerates the connection of generation to the grid. Unlock access to fast and accurate power system studies.
- Endolith — Endolith is a biotech company transforming sustainable mining by leveraging microbes, synthetic biology, and cloud computing to extract more critical minerals like copper from low-grade ores. Working with the many of the leading mining companies, Endolith is advancing its innovative technology to commercial scale. Recognized as a finalist in theBHP Unearthed BioMetals cohort and a member of the Alaska Critical Minerals Collaborative, Endolith is driving the future of mining with sustainable, efficient, and responsible solutions for the clean energy transition.
- Antora Energy — Antora converts low-cost, intermittent renewable electricity into a reliable, on-demand source of zero-emissions industrial heat and power.
Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.
Show more
Investment focus
- Biotechnology, Analytics, Health Care
- Series A, Seed, Series B
- Australia
Portfolio highlights
- Nexgen Plants — Healthy plants, healthy people, living planet. Nexgen develop's plants for future generations that will improve the environment and health of future generations.
- Icetana — icetana Motion Intelligence dramatically improves the active monitoring of security surveillance networks, with AI video anomaly detection and video analytics.
- Agworld — Agworld Farm Management software allows you to collect data at all levels and enables you to extract maximum value from this data; optimising profitability. The Agworld ecosystem is utilised by growers, agronomists and service providers on farms across the world.
Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Australia, United Kingdom
Portfolio highlights
- Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
- Elastagen — Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen hasdeveloped a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.
- AirXpanders — AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more
Investment focus
- Health Care, Biotechnology, Information Technology
- Seed, Series A, Funding Round
- United Kingdom, United States, Australia
Portfolio highlights
- Lumai — Lumai delivers fully optical computing for a quicker, smarter and more sustainable world. Lumai power the revolution of fully optical computing by working at the nexus of photonics and machine learning.
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Tenacious Ventures - Australia's first and only dedicated agrifood tech VC firm.
Show more
Investment focus
- Agriculture, AgTech, Biotechnology
- Seed, Series A, Pre-Seed
- Australia, United States
Portfolio highlights
- Goterra — Goterra's modular waste management systems use insects to process food and organic waste, converting it to sustainable protein and fertiliser
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
- Jupiter Ionics — Jupiter Ionics is a team of passionate scientists and engineers developing advanced electrochemical & carbon neutral Green Ammonia technologies.
Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.
Show more
Investment focus
- Software, Information Technology, E-Commerce
- Seed, Series A, Pre-Seed
- Australia, United States, Singapore
Portfolio highlights
- Voltavate — Voltavate is dedicated to driving innovation in battery technology to support the global transition towards sustainable energy solutions.
- Kite Magnetics — Electric motors enabling electric aircraft of all sizes to fly further, carry more and emit less. The future of aviation is electric.
- Quantum Brilliance — Quantum Brilliance builds room temperature quantum computers powered by synthetic diamond, enabling applications in everyday computing, including edge and massively parrellelized computing.
Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.
Show more
Investment focus
- Renewable Energy, Biotechnology, Energy
- Seed, Series A, Series B
- United States, United Kingdom, France
Portfolio highlights
- Trilobio — Biology is the future, but most lab technology is stuck in the past. Trilobio is rebuilding the biology lab from the ground up to unlock its true potential.
- Rainmaker Technology — Rainmaker uses drone-based cloud seeding to increase rainfall, restore ecosystems, and fight drought. Learn how our scalable weather technology brings water to the West.
- Breathe Battery Technologies — Breathe Battery Technologies is a research-led technology company developing advanced battery management algorithms
The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Series B, Series C, Funding Round
- United States, India, Austria
Portfolio highlights
- Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
- CXL Ophthalmics — CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.
Show more
Investment focus
- FinTech, Financial Services, Artificial Intelligence
- Seed, Series A, Series B
- United States, Hong Kong, Singapore
Portfolio highlights
- Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
- Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
- MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.
We Invest in the Circular Economy, a New Economic Model Focused on a Profitable and Sustainable Future.
Show more
Investment focus
- Recycling, Supply Chain Management, Artificial Intelligence
- Series A, Seed, Funding Round
- United States, United Kingdom, Chile
Portfolio highlights
- ClearCOGS — Operational Efficiency for the Modern Restaurant. Find out how clarity and profitable start with ClearCOGS.
- Supersede — Looking for sustainable lightweight waterproof plywood alternative. Upgrade your marine and construction projects with Supersede eco friendly materials.
- ChemFinity Technologies — ChemFinity Technologies is a chemical company that offers critical metal recovery, water purification, and gas separation services.
The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme
Show more
Investment focus
- Software, Real Estate, Financial Services
- Seed, Series A, Funding Round
- Australia, Germany, United States
Portfolio highlights
- MadeComfy — Award-winning Airbnb management service in Australia and New Zealand. MadeComfy is a selected official partner of Airbnb. Find out how we earn you higher returns with short-term rentals.
- Futurerent — Futurerent is a tool that offers solutions to residential property investors for investment capital and cashflow needs.
- Evrima Technologies — Our clinical trial recruitment and management services put participants first. Trusted, timely clinical trial results are a good thing - for everybody.
From idea to impact.
Show more
Investment focus
- Medical, Biotechnology
- Series B
- United Kingdom
Portfolio highlights
- PERKii — PERKii Targeted Release Probiotics are naturally micro-shielded to resist stomach acid up to 10,000x stronger than non micro-shield probiotics. For a targeted release in your gut and a difference you can feel. PERKii Probiotic Drinks are bottled with one billion or more probiotics per serve.
- Vicebio — [...]Read More... from Home
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
Queensland Investment Corporation is an investment company.
Show more
Investment focus
- Information Technology, Software, Financial Services
- Seed, Series A, Funding Round
- Australia, United States
Portfolio highlights
- Gelomics — Gelomics operates as a biotechnology company. Gelomics provides 3D cell culture technologies.
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
- Renewa — Renewa accelerates the transition to renewables by helping landowners achieve financial security and by providing capital solutions to developers.
Official website of Hitachi, Ltd. Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Pantomath — Pantomath is a data pipeline observability and traceability platform for automating data operations and improving data reliability through automated real-time monitoring and cross-platform pipeline lineage.
- Teramount — Teramount changes the world of optical connectivity by offering a novel solution, the patented PhotonicPlug, for connecting optics to silicon.
- Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.
Show more
Investment focus
- Software, Information Technology, Apps
- Seed, Series A, Funding Round
- Australia, United States, New Zealand
Portfolio highlights
- Auror — The platform for retailers focused on improving safety, productivity, and profitability. Auror is used by leading Loss Prevention teams in thousands of stores.
- Forever Network — Forever Network is a social-first sports media company. Our keystone brand, Basketball Forever, is the worlds largest independent sports media channel.
- Visionary Machines — Superior perception for next-generation autonomy
Empath Ventures is a venture capital firm that mainly invests in psychedelic medicine companies. The firm specializes in the fields of investment financial services, finance, and venture capital.
It was founded in 2021 and headquartered in Los Angeles California.
Show more
Investment focus
- Health Care, Biotechnology, Personal Health
- Seed, Pre-Seed, Convertible Note
- United States, United Kingdom, Canada
Portfolio highlights
- Xylo Bio — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
- Motif Neurotech — We're building DOT, a miniature brain stimulator designed to restore healthy brain activity in patients with treatment-resistant depression.
- Aperture Therapeutics — Aperture Therapeutics is building an innovative drug discovery platform that embraces the genetic diversity of patients and leverages mechanistic understanding of protective gene variants in the human population.
Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia.
Show more
Investment focus
- Events, Sports, Cycling
- Pre-Seed
- Hong Kong
Portfolio highlights
- Sineva — Sineva is a medical device manufacturing firm that makes ultrasonography simulators.
- VueMotion Labs — Optimize athletic performance with VueMotion's AI-driven movement analysis. Accessible, affordable, and trusted by pro teams worldwide. Start testing today!
- Neogenix Biosciences — NeoGenix Fertility: Selecting sperm for life through microfluidics and AI
The George Institute is on a mission to improve the health of millions of people worldwide. Join us in our fight for a healthier world.
Show more
Investment focus
- Biometrics, Health Care, Biotechnology
- Seed
- Australia
Portfolio highlights
- CellSync — CellSync is a Biotechnology Research firm that is working to make changes in the Future of Cell Engineering.
- Sineva — Sineva is a medical device manufacturing firm that makes ultrasonography simulators.
- Neogenix Biosciences — NeoGenix Fertility: Selecting sperm for life through microfluidics and AI
Allan Moss acts an adviser to Anchorage’s Investment Committee. Currently Principal of Allan Moss Investments, a private investment company, Allan retired from the role of Managing Director and Chief Executive Officer of Macquarie Group in May 2008. He was with Macquarie Group for 31 years and served as CEO from 1993 to his retirement in2008. He was also a non- executive director of CSR Ltd from 1996 to 2001.Allan graduated from Sydney University in Arts with a major in Economics and in Laws with Honours. He is also a graduate of Harvard University with a Masters Degree in Business Administration with High Distinction. Allan has received numerous industry awards and recognitions. He was twice named by Barron’s Magazine as one of the 30 most respected CEOs in the world (2006, 2007). He was appointed an Officer of the Order of Australia in 2005.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Funding Round, Series A, Seed
- Australia, United States, The Netherlands
Portfolio highlights
- Skykraft — Skykraft is an Australian space services firm that specializes in smallsat constellation design, production, and operation.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Invert Robotics — Invert Robotics develops robotic NDT inspection technologies for the maintenance of industrial equipment in the food and beverage, pharmaceutical, and oil and gas industries. Invert Robotics highly skilled team of engineers have developed a world leading modular inspection platform suitable for use across a range of industries and applications.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Seed, Pre-Seed, Series A
- Germany, Australia, United States
Portfolio highlights
- Heidi Health — Heidi Health is modernizing primary care with AI-powered technologies to improve care's quality and accessibility. its creators and engineers is to completely eradicate missed and sluggish diagnoses worldwide. They are committed to bridging the gap between the level of care that patients desire and the level of care that doctors can delivergiven their budget constraints. To create a platform where patients can quickly and easily get the treatment they require and to give every clinician the resources they need to deliver care that is secure, efficient,
- ViridiCO2 — ViridiCO2 technology transforms Carbon Dioxide into a variety of high-value chemical intermediates.
- SWARM Biotactics — SWARM Biotactics develops Biobots that enter, sense, and report where nothing else can.
Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more
Investment focus
- Medical, Health Care, Therapeutics
- Pre-Seed
- Australia
Portfolio highlights
- Cell Bauhaus — Cell Bauhaus uses mathematical and computer modeling to understand, predict, and modify living cell behavior, aiming to expedite sustainable solutions to humanity's pressing issues.
- Remagine Labs — Remagine Labs is revolutionizing healthcare with a bluetooth-connected, wearable electro-pharmaceutical that provide patient-centered care and consistent drug administration, giving healthcare customers peace of mind all over the world.
- Psychae Therapeutics — Psychae Therapeutics develop innovative pharmaceutical grade DMT-based medicines and therapies aiming to transform the lives of those facing some of the most prolific and insidious mental illnesses
Mike Wallas - Advisory Board @ Optifire Pty Ltd
Show more
Investment focus
- Video, Water, Biotechnology
- Seed, Funding Round
- Australia
Portfolio highlights
- PERKii — PERKii Targeted Release Probiotics are naturally micro-shielded to resist stomach acid up to 10,000x stronger than non micro-shield probiotics. For a targeted release in your gut and a difference you can feel. PERKii Probiotic Drinks are bottled with one billion or more probiotics per serve.
- Clipchamp — Create videos with royalty-free music and stock footage, use a pre-made video template, and export in up to 4K video resolution. Get started in-browser, download the Windows app, or create on the go with iOS app.
FINANCING SUCCESS IN OUR FOOD ECONOMY
Show more
Investment focus
- Wine And Spirits, Food and Beverage
- Seed
- United States
Portfolio highlights
- Ohza — Ohza crafts mouth-watering mimosas made with sparkling wine and real juice, but with fewer calories and less sugar. We're a ready-to-drink cocktail with good vibes only: all-natural, vegan, gluten-free, and preservative-free.
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
Gaingels is a leading venture investment syndicate in support of diversity, inclusive of the LGBTQIA+ community and allies in the venture capital space.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Seed, Series A, Series B
- United States, Canada, Mexico
Portfolio highlights
- Mana.bio — Mana.bio is an AI based drug delivery startup, focusing on gene therapy including RNA and DNA-based therapeutics and vaccines
- ZeroMark — ZeroMark is a defense product company building technology to ensure safety and precision when using kinetic and non lethal weapons.
- Wild West Systems — Wild West Systems is a Defense and Space Manufacturing firm developing weapon systems for the future war.
BioScience Managers Pty Ltd (formerly IB Managers) is a leading life sciences investment firm, headquartered in Melbourne, Australia. Established in 2003, BioScience Managers offers a global, multi-disciplinary team, bringing an international perspective together with the track record, networks and expertise required to convert that perspectiveinto informed, high return investment decisions.We operate a high value-add model, providing assistance and support to portfolio companies via our global team and international network of independent industry advisors. With combined experience of over 170 investments, more than 40 IPO’s/ reversals in Europe, the USA and Australia, and a diverse skillset specific to the bio-based industries, we aim to provide investee companies with significant value-add over and above capital invested.Alongside our funds management business, Phillip Bioscience Advisory provides specialist corporate advisory services to healthcare and life sciences companies.
Show more
Investment focus
- Health Care, Pet, Medical
- Funding Round
- Canada, Australia
Portfolio highlights
- Nexvet — Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs.Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines inhumans. We think it’s time companion animals reaped the benefits of human medical progress in this field.Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications.To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards.Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality.
- Canary Medical — Canary is giving medical devices a voice and letting medical data be heard.
The University of Sydney: A global top 25 university in Sydney, Australia, leading the way in addressing environmental, social, and governance challenges. Ranked 11th in the world for sustainability.
Show more
Investment focus
- Biotechnology, Therapeutics
- Pre-Seed, Series B
- Australia
Portfolio highlights
- Algenie — Algenie is an algae biotech company whose groundbreaking technology revolutionises algae production at scale, powering a sustainable economy.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Circulate Capital is an impact-focused investment management firm dedicated to financing innovation, companies, and infrastructure that prevent the flow of plastic waste into the world's oceans and advance the circular economy.
Show more
Investment focus
- Recycling, Biotechnology, Manufacturing
- Funding Round, Seed, Series B
- United States, India, Indonesia
Portfolio highlights
- Recykal — Recykal is a digital technology company powering a marketplace, building Saas, cloud based solutions for Waste management, recycling industry. Recykal also provides technology solutions for smart cities, municipal corporations and EPR services to FMCG, electronics companies
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
- Ricron Panel — Manufacturer and supplier of high-quality building materials that are waterproof, rustproof, heat resistant, recyclable, lightweight, and fire retardant. We help businesses source sustainable materials for their operations.
Thistledown Foundation is a private charitable foundation.
Show more
Investment focus
- CleanTech, Construction, Biotechnology
- Series A, Funding Round
- Canada, Australia
Portfolio highlights
- Avnos — Our HDAC solution offers the broadest geographic potential available, enabling our technology to operate in water-scarce environments.
- Loam Bio — Loam has designed farmer-focused carbon projects that support farmers to build stable soil carbon in cropping and mixed farming systems.
- CarbonCure Technologies — CarbonCure Technologies creates, develops, and licenses solutions that consume waste CO2 to make better concrete. It spurs the market shift towards affordable green concrete, by enabling concrete manufacturers to convert waste CO2 into solid minerals, locked away as a solid within concrete during manufacturing. It is a green building technologycompany currently serving concrete product manufacturers in the US and Canada. It offers concrete producers the ability to manufacture green concrete products without compromising on either quality or price.CarbonCure is a retrofit innovation that repurposes CO2 gas from large final emitters as a feedstock in concrete plants. The gas is permanently converted into embedded solid mineral carbonates that yield material, environmental, and production advantages. By enabling concrete manufacturers to consume CO2 into concrete products during manufacturing, the technology differentiates an otherwise traditional commodity concrete product, while achieving superior material performance characteristics. In addition to technology, CarbonCure provides demand-pull marketing and environmental reporting/certification services to reinforce its customers’ exclusive competitive positioning. The technology is licensed at a very low-CAPEX to concrete producers, generating a recurring revenue stream.CarbonCure Technologies was founded in 2007 and is headquartered in Halifax, Nova Scotia.
Australian Nuclear Science and Technology Organisation is one of Australia's most important research infrastructures. Thousands of scientists in industry and academia gain access to state-of-the-art instruments every year. ANSTO operates much of Australia's landmark infrastructure, including OPAL, one of the world's most advancednuclear reactors; the Australian Synchrotron; the National Imaging Facility Research Cyclotron; and the Centre for Accelerator Science.
Show more
Investment focus
- Health Care, Biotechnology, Pharmaceutical
- Funding Round
- Australia
Portfolio highlights
- Clarity Pharmaceuticals — Clarity is a clinical stage company developing products to address the growing need for the use of radiopharmaceuticals in oncology.
Loyal runs a global venture fund with quarterly redemptions and a proprietary gate-stage process, reducing investment bias and unlocking greater returns. Partnered with INSEAD, Founder Institute, and 500+ advisors, we are Loyal to the world with 250+ investments in 50+ countries.
Show more
Investment focus
- Artificial Intelligence, Software, E-Commerce
- Pre-Seed, Seed, Funding Round
- United States, Canada, United Kingdom
Portfolio highlights
- WASTETIDE — We cut the costs and carbon footprint of waste.
- Bagel AI — Bagel AI is a product intelligence platform that automates product management, helping product teams turn data into insights, streamline GTM, and drive growth
- Aisel Health — Aisel Health provides AI that imitates psychiatrists for psychiatric clinics and hospitals to ensure efficient patient access to care.
Time Ventures is an investment fund for Marc Benioff. The company looks to invest in theB2B, hospitality, non-financial services, and commercial products and services sectors.
Show more
Investment focus
- Software, Information Technology, Artificial Intelligence
- Series A, Series B, Seed
- United States, Canada, Germany
Portfolio highlights
- Moonhub — Hire Top Talent On Demand With Expert Recruiters and AI
- CarbonCapture — CarbonCapture Inc. is a direct air capture company creating technologies to decarbonize the atmosphere. Contact us if you're interested in our mission.
- Siolta Therapeutics — Siolta Therapeutics is harnessing science from the human microbiome to design next-generation microbial therapeutics. Learn more.
Terra Rossa Capital Pty Ltd operates as a venture capital fund. The Company invests in life science companies. Terra Rossa Capital serves clients in Australia.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Series A, Series B
- Australia
Portfolio highlights
- Signostics — Signostics produces Biotech medical devices. Their flagship product, Signos, allows healthcare professionals to use ultrasound in their clinical practice. It offers ultrasound platform technology that clinicians can place in their pocket or wear around their neck like a stethoscope. Just as handheld devices transformed the business world, it isanticipated the Signos will change the way healthcare professionals practice medicine.Signostics was established in Adelaide, Australia in 2005 and expanded into the U.S. in 2008, dedicated to developing fast and affordable pointâ€ofâ€care medical devices. The company launched its first product into the veterinarian market in January 2009 andgained regulatory approvals to enter the human medical device market for the United States, Europe, and Australia in May 2009. Signostics has offices in Palo Alto, California and Adelaide, South Australia.
South Australian Venture Capital Fund - helping build dynamic and innovative South Australian startups / scaleups and accelerate their growth to a national and global scale.
Show more
Investment focus
- Health Care, Biotechnology, SaaS
- Funding Round, Series A, Series B
- Australia
Portfolio highlights
- Lumary — Simplify Your Care Management Optimise Your Organisation Create Better Wellbeing
- BiomeBank — BiomeBank is a clinical stage biotechnology company with a mission to treat our microbiome and prevent disease by restoring gut microbial ecology.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
Investors by industry
Google
Marketplace
Hardware
Energy
Proptech
Health Care
Biotech
Artificial intelligence
Climate
Consumer
Community
Impact
Gaming
FinTech
EdTech
Sustainability
Venture Capital
Big Data
Web3
B2B
Financial Services
Finance
Infrastructure
Education
Photography
Payments
Food and Beverage
Video Games
Organic Food
Retail
Beauty
Publishing
Clean Energy
Real Estate
Manufacturing
Art
Music
Android
Internet
Enterprise Software
eSports
Franchise
Sports
Construction
Digital Media
Email
Medical
Social Network
Wellness
Social Media
Mobile
Legal
Local
Recruiting
Cannabis
Platforms
Fitness
Travel
Mobile Advertising
Biotechnology
Hospitality
Social
Automotive
Crowdfunding
Wine And Spirits
Medical Device
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Theatre
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
United Kingdom
Canada
South Korea
Ireland
United States
New Zealand
India
Germany
Australia
Armenia
South Africa
Spain
Japan
Africa
China
Bulgaria
Sri Lanka
Belize
Bahrain
Croatia
Singapore
Georgia
Belarus
Hungary
France
Ghana
Ethiopia
Gibraltar
Chile
Egypt
Finland
Costa Rica
Greece
Barbados
Belgium
Estonia
Qatar
Bermuda
Czech Republic
Denmark
Algeria
Asia
Hong Kong
Ecuador
Faroe Islands
Liechtenstein
Liberia
Lebanon
Mauritius
Peru
Indonesia
Norway
Israel
Malaysia
Mexico
Nicaragua
Vietnam
Jersey
Panama
Morocco
Mali
Lithuania
Italy
Philippines
Kuwait
Malta
Myanmar
Oceania
Sierra Leone
El Salvador
Uganda
Venezuela
Sweden
Slovenia
Poland
Uruguay
Ukraine
LATAM
Tajikistan
Puerto Rico
Portugal
Tunisia
Taiwan
Tanzania
Middle East
Turkey
San Marino
Senegal
Togo
Uzbekistan
Serbia
Russian Federation
Zambia
Rwanda
Zimbabwe
Thailand
Europe
Dominican Republic
Azerbaijan
Iceland
Saudi Arabia
Nigeria
Bahamas
Namibia
Iraq
United Arab Emirates
Jamaica
Honduras
Isle of Man
Brazil
Bolivia
Luxembourg
Pakistan
Albania
Grenada
Jordan
Romania
Bangladesh
Argentina
Kazakhstan
Kenya
Cayman Islands
Cambodia
Oman
Latvia
Cyprus
Austria
Switzerland
Cameroon
Colombia
Guatemala
Seychelles
Marshall Islands
Investors in Australia by industry
Enterprise
FinTech
Consumer
Health Care
EdTech
Climate
Proptech
SaaS
Community
Hardware
Gaming
Restaurants
Crowdfunding
Venture Capital
Mobile Apps
Oil and Gas
Real Estate
Medical Device
Cryptocurrency
Finance
Food and Beverage
Organic Food
Wine And Spirits
Renewable Energy
Video Games
Medical
Wellness
Email
Artificial intelligence
Internet
Social Media
Social Network
Art
Digital Media
Music
Android
Blockchain
Local
Construction
Legal
Software
Enterprise Software
Sports
Biotech
eSports
Fitness
Hospitality
CleanTech
Automotive
Travel
InsurTech
Recruiting
Biotechnology
Cannabis
Impact
Mobile
Retail
Social
Infrastructure
Fashion
Beauty
Web3
B2B
Sporting Goods
Publishing
Big Data
Clean Energy
Financial Services
Non Profit
Energy
Platforms
Education
Manufacturing
Marketplace
Agriculture (agtech)
Media (entertainment)
Machine Learning
Life Science
Payments
Sustainability
Social Impact
Transportation
Photography